medicaid semaglutide Louisiana lawmakers are considering a bill that would expand access to GLP-1 drugs for obesity treatment, a move supporters say could improve health outcomes and reduce long-term costs. https://bit.ly/4usEGVI As demand for weight-loss drugs

showed comparable amounts of DA release either in response to amphetamine or to a (conditioned) placebo 20 , suggesting that a relatively strong DA release in the context of our learning study appears plausible and is consistent with a general role for DA in learning about rewards rather than reward per se

Emerging research suggests that GLP-1 receptor agonists may exert anti-inflammatory effects through multiple pathways, potentially even at doses lower than those typically used for diabetes or weight management

Think of it as a progressive skin rejuvenation that gets better week by week

A sustainable GLP-1 cost-management strategy should include more than medication coverage alone